Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "als treatment"

GrantRSS2 days ago

Outsee wins award to support AI search for ALS treatments

A company called Outsee won a major award worth about $10 million to use artificial intelligence and patient genetic information to find new ways to treat ALS, a disease that affects nerve cells in the brain and spinal cord. This award is part of a larger global competition called the Longitude Prize on ALS that aims to speed up the discovery of new treatments for this serious condition.

WHY IT MATTERSThis funding could accelerate the discovery of new ALS treatment targets by combining AI technology with real patient genetic data, potentially leading to novel therapies for a disease with limited treatment options.
ℹ Good to knowamyotrophic lateral sclerosis
PipelineRSSMay 7

ALS treatment tazbentetol gets FDA fast track status

The FDA has given fast-track status to tazbentetol, a new oral medication being developed by Spinogenix for ALS (a disease that affects nerve cells that control muscles). Fast-track status means the FDA will review this drug more quickly and the company can talk with FDA regulators more often during development. This designation is given to treatments for serious diseases where there aren't many good options available.

WHY IT MATTERSFast-track designation could bring tazbentetol to ALS patients 1-2 years sooner than standard FDA review timelines, which is critical since ALS progresses rapidly and patients have limited treatment options.
👁 Watch this spaceamyotrophic lateral sclerosis
GrantRSSMay 6

Acurastem wins $7.5M to advance ALS treatment to clinical trials

A company called Acurastem received $7.5 million in funding to help develop a new treatment called AS-241 for ALS (a disease that affects nerve cells that control muscles). Early lab studies show this treatment might be able to fix problems caused by a faulty protein called TDP-43. The company is now working to get this treatment ready to test in patients.

WHY IT MATTERSThis funding accelerates a potential new ALS treatment toward human trials, offering hope for patients with TDP-43-related ALS who currently have limited therapeutic options beyond supportive care.
👁 Watch this spaceamyotrophic lateral sclerosisALS
Clinical trialRSSApr 30

Developer gets OK to expand first-in-human trial of ALS therapy to Europe

A company called Vectory Therapeutics has received permission to test its experimental ALS drug, called VTx-002, at hospitals in the United Kingdom and European Union. The drug is already being tested in the United States as part of a Phase 1/2 clinical trial. This expansion means more patients in Europe may have the opportunity to participate in this early-stage study of a potential new ALS treatment.

WHY IT MATTERSALS patients in the U.K. and EU now have access to a first-in-human trial for a novel therapy, potentially expanding treatment options beyond currently available medications for this rapidly progressive disease.
💬 Ask your doctoramyotrophic lateral sclerosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases